Skip to content

Device Use Reimagined Through Education And Mentorship

Optimizing Diabetes Technology Use for Latinx Youth Through DREAM (Device Use Reimagined Through Education And Mentorship) Virtual Peer Groups [Study-wide] - DREAM Intervention

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06546930
Acronym
DREAM
Enrollment
120
Registered
2024-08-09
Start date
2024-10-11
Completion date
2026-07-31
Last updated
2026-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 1

Keywords

T1D, Diabetes, Diabetes Mellitus, Type 1

Brief summary

Diabetes technology, such as insulin pumps and continuous glucose monitoring devices, can help improve glucose control for people with type 1 diabetes (T1D), which keeps them at lower risk for diabetes complications, but many Latinx adolescents, who make up the largest marginalized ethnic group of youth with T1D in California, use these devices less often and have less optimal glucose control compared to White youth. In phase 1 of this project, we worked directly with Latinx youth, their families, and diabetes care team members in California to develop DREAM, Device use Reimagined through Education And Mentorship, a virtual peer group (VPG) intervention that will encourage and support the use of diabetes devices in Latinx adolescents with T1D. The goals for phase 2 (intervention) of this project are to evaluate the feasibility and acceptability of the stakeholder-informed VPG intervention, and evaluate clinical and person-centered outcomes.

Detailed description

This multi-site project has two phases: phase 1 involved stakeholders focus groups to assess barriers and facilitators to diabetes technology and the creation of advisory councils. Feedback was obtained and used to develop phase 2, the single arm trial. A virtual peer group curriculum is being refined and will be implemented. The aims of this project are: (1) Partner with stakeholders to design a virtual peer group (VPG) intervention to promote the initiation and continued use of diabetes technology among Latinx adolescents with T1D. (2) Evaluate the feasibility and acceptability of DREAM VPGs in a pragmatic, single arm trial. (3) Assess the effects of DREAM VPGs on clinical and person-centered outcomes. Our DREAM intervention will: * Build trust/rapport and "relational connections" between participants * Empower participants to be advocates in their/their adolescents' diabetes care * Provide tools/knowledge to navigate healthcare and diabetes technology systems * Increase knowledge, confidence, and interest in using diabetes technology * Create a culturally sensitive/inclusive VPG toolkit that will be scalable, feasible, and sustainable in broader clinical contexts if found to be beneficial The DREAM project's findings will inform future efforts to improve diabetes technology use and T1D health outcomes among Latinx adolescents. If found to be effective, the VPG curriculum can be adapted for other clinic settings in order to improve education and peer support for Latinx patients and families. Future studies may extend or adapt DREAM to other cohorts, including other age groups, geographic settings, or marginalized and historically excluded populations with T1D.

Interventions

BEHAVIORALDREAM intervention

Virtual Peer Groups (VPGs) Participants will have multiple opportunities to attend a VPG on a specific topic during their 6-12 month participation period. The VPG topics will include the following: * Diabetes technology - basics or advanced use (audience-dependent) * Family relationships and diabetes * Diabetes in real life - school, work, social gatherings, travel * Wellbeing and support when living with diabetes * Working with your diabetes care team - who to call for what * Eating and activity - what's different with T1D? In-Person Events will be held quarterly to facilitate participant interaction and community-building. These gatherings will feature ice-breaker activities, refreshments, and hands-on learning opportunities, including the chance to interact with specific diabetes devices and engage with healthcare professionals and representatives from diabetes technology companies.

Sponsors

University of California, San Francisco
Lead SponsorOTHER
Children's Hospital Los Angeles
CollaboratorOTHER
University of California, Davis
CollaboratorOTHER
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

Intervention group (will receive VPG curriculum) versus comparator group (not enrolled)

Eligibility

Sex/Gender
ALL
Age
13 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

* Adolescents 13-17 years old and their caregivers * Adolescent must have T1D of any duration, and be receiving diabetes care at UCSF, CHLA or UC Davis * Self-identify as Latina/o/x or other variations such as Hispanic * Preferred language of English or Spanish

Exclusion criteria

* Participants who have a medical, developmental, or psychiatric condition that would make peer group participation difficult * Adolescents who are planning to transfer care to a different medical center within the next year, which would prevent assessment of longitudinal outcomes

Design outcomes

Primary

MeasureTime frameDescription
Caregiver SurveyBaselineCaptures personal and family background (e.g. gender, income)
Caregiver Phase 2 Intervention Survey - "Feedback Survey"End of Study to (6-15 months)Assess various intervention components (e.g., frequency of virtual peer groups, in person events).
Caregiver In Person Event EvaluationThroughout the study, up to 15 monthsCaptures in the moment in person event feedback (e.g., improve experience and components).
Caregiver Online Group EvaluationThroughout the study, up to 15 monthsCaptures moment group feedback (e.g., improve experience and content).
Adolescent SurveyBaselineCaptures diabetes technology, personal and family background (e.g., diabetes technology history, gender).
Adolescent Phase 2 Intervention Survey - "Feedback Survey"End of Study (6-15 months)Assess various intervention components (e.g, frequency of virtual peer groups, in person events).
Adolescent In Person Event EvaluationThroughout the study, up to 15 monthsCaptures in the moment in person event feedback (e.g., improve experience and components).
Adolescent Online Group EvaluationThroughout the study, up to 15 monthsCaptures moment group feedback (e.g., improve experience and content).
Attendance at VPG and in-person eventsThroughout the study, up to 15 monthsAttendance will be recorded for each in person and online events
Retention of enrolled patientsEnd of Study (6-15 months)Engagement of participants throughout study trajectory

Secondary

MeasureTime frameDescription
Caregiver Diabetes Distress Scale (DDS)Baseline and End of Study (6-15 months)Measures parent-related distress, person distress, teen management distress, parent/teen relationship distress and healthcare distress, response options for each item were provided on a 5-point Likert scale, higher score indicated more distress.
Caregiver Diabetes Family Conflict Scale (DFCS)Baseline and End of Study (6-15 months)Measures negative emotions around BGM, quality of life, and perceived parental burden from diabetes management; 3-point Likert scale, higher score indicating more conflict.
Caregiver Health Care Relationship (QHR)Baseline and End of Study (6-15 months)Captures interactions with medical team, response options for each item were provided on a 5-point Likert scale in various formats.
Patient Health UtilizationBaseline, 3-months, 6-months, 9-months, End of Study 12 to 15-monthsAsks about any interval ED or hospital utilization over the prior 3 months
Adolescent Diabetes Distress Scale (DDS)Baseline and End of Study (6-15 months)Measures diabetes emotional distress; response options for each item were provided on a 5-point Likert scale, higher score indicated more distress.
Adolescent Benefits and Burdens of CGM (BenCGM & BurCGM)Baseline and End of Study (6-15 months)Measures benefits and burdens of continuous glucose monitoring in adolescents; 5-point Likert scale.
Adolescent Diabetes Family Conflict Scale, (DFCS)Baseline and End of Study (6-15 months)Measures negative emotions around BGM, quality of life, and perceived parental burden from diabetes management, 3-point Likert scale, higher score indicating more conflict.
Adolescent Diabetes Strengths and Resilience Measure (DSTAR)Baseline and End of Study (6-15 months)Captures adaptive aspects of adolescents' diabetes management (i.e., "strengths"), and is related to clinical outcomes, 5-point Likert scale.
Adolescent BenPump/Pod & BurPump/PodBaseline and End of Study (6-15 months)Measures benefits and burdens of pump/pods monitoring in adolescents, 5-point Likert scale.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORJenise C Wong, MD, PhD

University of California, San Francisco

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 2, 2026